Navigation Links
Savara Closes Second Tranche of Series A Financing Round, Receives Allowance for Base Patent
Date:12/16/2009

AUSTIN, Texas, Dec. 16 /PRNewswire/ -- Savara, Inc., an inhalation drug delivery company, today announced that it has closed the second tranche in its Series A financing round, exceeding the targeted total raise amount of $1.4 million.

Funds raised in the Series A round will be utilized to continue the development of the NanoCluster technology.

"We now have the runway and resources to effectively demonstrate the scalability and performance of the NanoCluster technology," said Rob Neville, CEO of Savara.

The company also announced that it has received patent allowance from the United States Patent and Trademark Office (USPTO) for its core NanoCluster technology. The patent covers its unique formulation of inhalation particles that are composed of drug nanoparticles agglomerated together (US Patent No. 11/610,986).

"Allowance on our base patent is a significant milestone in our company's history. This proprietary position is strategically important to Savara and our partners as we utilize the NanoCluster technology to improve patient health in areas of unmet need," said Neville.

About Savara's NanoCluster Technology

Particle size is critical for pulmonary drug delivery, and the ability to obtain particle sizes in the range of 1-3 microns has the potential to improve the efficacy of existing and new drug therapies. Savara's NanoCluster technology utilizes nanotechnology to formulate high performance inhalation powder without the need for novel excipients or carrier particles. Savara's NanoClusters are modeled after naturally occurring aerosols, which are highly effective in reaching the peripheral lung. These aerodynamics enable high drug concentrations in specific regions of the lung, independent of the inhalation flow rate. Savara expects that NanoCluster's unique features will enable products that are currently difficult or impossible to develop using conventional inhalation powders.

About Savara, Inc.

Savara, Inc. (www.savarapharma.com) is a drug delivery company based in Austin, Texas and a member of the Austin Technology Incubator. Savara has an exclusive license to the NanoCluster technology from the University of Kansas. Savara's NanoCluster technology is currently available for evaluation and licensing.



    Contact Information

    Media:
    Ian Stone
    Russo Partners, LLC
    (619) 528-2220
    Ian.Stone@russopartnersllc.com

    Partners & Investors:
    Rob Neville
    (512) 961-1891 x2
    rob.neville@savarapharma.com


SOURCE Savara, Inc.


'/>"/>
SOURCE Savara, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. BioVascular Inc. Closes $10.87 Million Series C Financing
2. MabVax Therapeutics Closes Two Licensing Agreements With Sloan-Kettering Institute for Cancer Research
3. DNA Therapeutics Closes 2.2 Million EUR Series A Financing Round
4. Cognition Therapeutics Closes Series A Financing to Advance Drug Candidates for Alzheimers Disease
5. Curemark Closes Series A Financing
6. Blue Belt Technologies, Inc. Closes Series A Financing
7. Caraco Pharmaceutical Laboratories, Ltd. Closes Asset Purchase Agreement with Forest Laboratories, Inc. to Settle Lexapro(R) (escitalopram oxalate) ANDA Patent Litigation
8. American Scientific Resources Inc. Discloses Audited Financials for 2007 and 2008
9. Keraderm Closes on $2.5 Million Investment from NewVa Capital Partners, LP
10. Aethlon Medical Discloses Live Webcast of Todays BIOCOM Presentation
11. Boehringer Ingelheim Animal Health Closes Deal to Acquire a Significant Portion of the Fort Dodge Animal Health Business From Pfizer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/7/2017)... 7, 2017 NuvoAir (formerly called Pond ... today a partnership with Novartis Pharma AG to distribute NuvoAir,s ... as the leading mobile spirometry platform and Novartis, commitment to ... ... ...
(Date:9/7/2017)... BioLife Solutions , Inc. (NASDAQ: BLFS ), the ... and tissue hypothermic storage and cryopreservation freeze ... and CEO, will be presenting at two investment conferences in ... th Annual Global Investment Conference on Tuesday, September 12th, ... conference is being held at the New York Palace Hotel ...
(Date:9/6/2017)... Sept. 6, 2017  Medical professionals are ... skills while treating their patients. Medical simulations ... without involving patients. Simulation provides a safe ... carry out procedures, refine techniques and build ... of new technology, such as augmented reality, ...
Breaking Medicine Technology:
(Date:9/19/2017)... , ... September 19, 2017 , ... Premiere Long Island ... Sami, was recently named one of the best dentists in America under age 40 ... dental professionals nationwide. Every fall, the magazine features the best 40 dentists under the ...
(Date:9/19/2017)... , ... September 19, 2017 , ... ... Inc. 5000 , the most prestigious ranking of the nation's fastest-growing private companies. ... American economy’s most dynamic segment— its independent small and midsized businesses. Endo-Systems is ...
(Date:9/18/2017)... ... ... set of dissolving transitions created for use within Final Cut Pro X . ... without the use of keyframes. Choose to bleed away darks and lights to ... to gradually dissolve away the light in a scene to reveal the following scene. ...
(Date:9/18/2017)... ... 18, 2017 , ... Cosmetic Town, an online plastic surgery and information community, ... of Cosmetic Tow, “Our forum section is an interactive, and popular, section of the ... members thinking about having cosmetic surgery. The interaction and sharing among our forum ...
(Date:9/18/2017)... ... September 18, 2017 , ... In the age of digital media, limiting ... distractions are readily available and a convenient way to soothe fussy children. , According ... make the switch to sensory development toys completely. , The study, entitled “Is handheld ...
Breaking Medicine News(10 mins):